about
Design, characterization, and clinical evaluation of argan oil nanostructured lipid carriers to improve skin hydrationLipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes.Lipid nanoparticles for the delivery of biopharmaceuticals.Nucleic Acids Delivery Systems: A Challenge for Pharmaceutical Technologists.Delivery Systems for Biopharmaceuticals. Part I: Nanoparticles and Microparticles.Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers.Scaffolds for Bone Regeneration: State of the Art.Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.Editorial: therapeutic applications of advanced drug delivery systems.Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activity.Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases.Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review.Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticlesSolid lipid nanoparticles (SLN) - based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: Preparation and characterization studiesEditorial: Applications of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): State of the ArtNose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisisBiosimilar medicines used for cancer therapy in Europe: a reviewInsights on the Formulation of Recombinant ProteinsCytokines and Growth Factors
P50
Q28392702-51BC0802-E813-46A7-B56E-9E73278B35FDQ38029748-68A18BD7-C86F-476F-A099-95D8E6580699Q38324429-1C3FDE3E-89D2-4DC2-81AE-5DB27D697DE2Q38398322-3A6CA8CA-B1AE-4881-B571-66DD726E41A8Q38560033-08F15F4E-28F2-478C-9108-29EF27A66BB8Q38567718-8E236DC7-C121-4783-81DC-C09E21A8D4A2Q38722991-6C732276-0ED2-40C2-B937-5923203F10C4Q38935547-5EA038F2-C868-49A0-9463-07EA9AB925CCQ45068992-49792FD2-7CFA-43A9-B676-6C64C92688ACQ45736422-5A4DE618-0936-4147-BB3B-9C2E71CE26D6Q47943181-5132E8A4-A2A4-44AB-8BAB-69D1901EC517Q49567719-05A708BF-D740-4151-B7AE-B6915D2F0E4BQ61818358-61EA8355-C033-4D7F-A481-01897EA7437BQ61818368-57DA7B75-BE0C-41C3-80E5-E1740AD4E1D2Q89626973-54867B63-E9D1-474D-A973-AF9E7C4804A7Q90899731-77BF998A-D050-47C5-BA6E-3F774FE7B0F5Q91654831-E68D83F0-3DCF-49E9-A447-829923DE00D8Q92031090-6C53EFF8-8D2E-42A9-805D-C0DCEE754D25Q92438863-7C0B5DB0-5A8E-4B6B-BDFB-48E1023B6E89
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ana Catarina Silva
@ast
Ana Catarina Silva
@en
Ana Catarina Silva
@es
Ana Catarina Silva
@nl
type
label
Ana Catarina Silva
@ast
Ana Catarina Silva
@en
Ana Catarina Silva
@es
Ana Catarina Silva
@nl
prefLabel
Ana Catarina Silva
@ast
Ana Catarina Silva
@en
Ana Catarina Silva
@es
Ana Catarina Silva
@nl
P108
P106
P1153
57028697500
P21
P31
P496
0000-0001-6923-0232